ArticleBritish journal of cancer2020

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.

Johann de Bono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.